Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30484265 | 1.00 | DHFR (0.48) | DHFRSMN1; SMN2TSHRRXRARXRB | |
| SCHEMBL16902897 | 0.89 | TSHR (0.47) | SMN1; SMN2TSHRTAAR1 | |
| SCHEMBL13803109 | 0.85 | TSHR (0.45) | DHFRSMN1; SMN2TSHRTAAR1ALDH1A1 | |
| SCHEMBL27688854 | 0.85 | TAAR1 (0.46) | SMN1; SMN2TSHRTAAR1ALDH1A1HTT | |
| SCHEMBL1416835 | 0.85 | CYP4F2 (0.56) | DHFRSMN1; SMN2RXRARXRBP2RX3 | |
| SCHEMBL759473 | 0.84 | CHRNB4 (0.43) | DHFRSMN1; SMN2TSHRTAAR1FFAR4 | |
| SCHEMBL758042 | 0.84 | TSHR (0.44) | SMN1; SMN2TSHRTAAR1GAAHSD17B10 | |
| SCHEMBL13803187 | 0.84 | TSHR (0.44) | SMN1; SMN2TSHRTAAR1GAAHSD17B10 | |
| SCHEMBL1908523 | 0.82 | MAPK1 (0.49) | DHFRSMN1; SMN2TSHRRXRARXRB | |
| SCHEMBL2939051 | 0.82 | CYP2C9 (0.51) | SMN1; SMN2TSHRALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304542-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| WO-2023069700-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2855431-B1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (NL) | 2016-07-06 | — | — | EP | disclosed |
| EP-2855431-B1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (NL) | 2016-07-06 | — | — | EP | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-9044463-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-06-02 | — | — | US | disclosed |
| US-9044463-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-06-02 | — | — | US | disclosed |
| US-9044463-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-06-02 | — | — | US | disclosed |
| US-6106999-A | SENSITIVITY TO GENERAL-PURPOSE VISIBLE LIGHT LASER, SO THAT HIGH-SPEED SCANNING EXPOSURE IS POSSIBLE BY LASER, AND EXTREMELY FINE HIGH RESOLUTION CAN BE OBTAINED; CAN BE USED FOR COATING OR PRINTING UNDER SAFELIGHT IRRADIATING CONDITIONS | MITSUI CHEMICALS (JP) | 2000-08-22 | — | — | US | disclosed |
| US-5631264-A | NEUROLOGICAL DISORDERS | SANOFI WINTHROP, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| US-5554620-A | Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof | STERLING WINTHROP INC. (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0656359-A1 | Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof | STERLING WINTHROP INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0648769-A1 | 12-Hetero-substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizium salts and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1995-04-19 | — | — | EP | disclosed |
| US-5380729-A | Treatment or prevention of neurodegenerative disorders or neurotoxic injuries | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0093010-B1 | ALPHA-HYDROXYETHYLPHOSPHINATES, AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-06-11 | — | — | EP | disclosed |
| US-4554111-A | α-Hydroxyethylphosphinates, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-11-19 | — | — | US | disclosed |
| US-4544652-A | α-Hydroxyethylphosphinates, and their use as fungicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-10-01 | — | — | US | disclosed |
| EP-0093010-A2 | Alpha-hydroxyethylphosphinates, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304542-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | DHFR 154/4885SMN1; SMN2 4732/4885TSHR 3919/4885 |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | DHFR 1303/4885SMN1; SMN2 2227/4885TSHR 3902/4885 |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | DHFR 250/4885SMN1; SMN2 1563/4885TSHR 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.